Kybella and Belkyra are both injectable treatments designed to reduce submental fullness, commonly known as a double chin. While they share the same active ingredient, deoxycholic acid, their branding and availability differ based on geographical location. In essence, Kybella is the name used in the United States, while Belkyra is its counterpart in Canada and other international markets. Both treatments are effective in reducing double chin, but the choice between them often depends on regional availability and clinician preference.
Understanding the Active Ingredient
The active ingredient in both Kybella and Belkyra is synthetic deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the submental area, this acid destroys fat cells, resulting in a noticeable reduction in fullness under the chin. Over time, the body naturally metabolises the destroyed fat cells, leading to a more contoured jawline. Despite their different names, the mechanism of action for both treatments is identical, ensuring similar efficacy in reducing double chin.
Treatment Procedure and Expectations
Both Kybella and Belkyra are non-surgical procedures that involve a series of injections administered by a trained healthcare professional. The number of sessions required varies depending on the patient’s desired outcome and the amount of submental fat present. Typically, patients undergo two to four sessions spaced several weeks apart. Patients might experience mild side effects such as swelling, bruising, or numbness, which generally subside within a few days. It is crucial for potential candidates to consult with a qualified practitioner to determine if they are suitable for the treatment and to discuss expected results.
Considerations for Choosing Between Kybella and Belkyra
When deciding between Kybella and Belkyra, the primary consideration should be the geographical availability of the product. Since both treatments are essentially the same, the decision may also depend on the familiarity and comfort of the practitioner with either brand. Additionally, patients should consider any potential cost differences and consult with their healthcare provider to understand the full scope of the treatment, including any post-treatment care required. Ultimately, whether opting for Kybella or Belkyra, patients can expect a reduction in submental fat and an enhanced facial profile.
Both Kybella and Belkyra offer effective solutions for reducing a double chin through the same active ingredient, deoxycholic acid. They are identical in function and purpose, differing only in name and regional availability. The choice between the two often comes down to where the treatment is being administered, as Kybella is more commonly available in the United States, while Belkyra is found internationally.
Patients can expect similar results from either treatment, with the number of sessions varying based on individual needs and the amount of submental fat. The procedure involves minimal downtime, which appeals to those seeking non-invasive cosmetic enhancements. It is crucial for patients to consult with a qualified professional to establish a treatment plan tailored to their specific goals.
Ultimately, the decision between Kybella and Belkyra should be guided by the availability of the product in the patient’s region and the expertise of their chosen practitioner. Both options promise effective reduction of submental fullness, offering patients a more contoured appearance.
